Tags: dart therapeutics, executive team
add a comment
On September 10th MBBP client DART Therapeutics LLC announced it has named its new Executive Team including co-founder and executive chairman, Gene W. Williams as its CEO. Founded in 2010 by Williams and patient foundations the Nash Avery Foundation and Charley’s Fund, DART is a patient-funded biotech business focused on Duchenne Muscular Dystrophy (DMD) and other rare diseases. In addition to Williams, DART also appointed Ernest Bush as chief scientific officer; Dr. Elliot Goldstein as its chief medical officer; and Cabot Brown as chief financial officer.
For more information, please see the full press release.
Tags: dart therapeutics, do-it-yourself drug development, duchenne muscular dystrophy
add a comment
On December 27th, the Wall Street Journal‘s Heath Blog published a post on MBBP client Dart Therapeutics, a company focused on developing treatment for Duchenne muscular dystrophy (DMD). Dart Therapeutics was formed by two families, the Secklers and Wickas, who each have a son diagnosed with DMD, a genetic neuromuscular disorder. They were frustrated with the lack of research and experimental drug development programs for DMD and decided to form their own company Dart Therapeutics. Set up with the purpose of “identifing potential compounds, making deals, and developing the drugs”, Dart Therapeutics created a new innovative business model, one in which the blog posting describes as a ” do-it-yourself drug development”. Ultimately, the goal of Dart is not only to help do-it-yourself drug development for Duchenne but also other orphan diseases that can use outside experts to negotiate deals, oversee experiments, and work with the FDA.
Please read the full article for more information.